VEGFA and diabetic retinopathy: Still, the advent of anti-vascular endothelial growth factor (anti-VEGF) agents, including ranibizumab, bevacizumab, and aflibercept, presents successful therapeutic options. This study aims to conduct a systematic review and meta-analysis to compare the efficacy of anti-VEGF therapy combined with vitrectomy versus vitrectomy alone in patients with vitreous hemorrhage due to diabetic retinopathy. Many electronic sources, such as PubMed and Google Scholar, were searched for pertinent literature.